The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.

The U.S. Food and Drug Administration approved Melinta Therapeutics’ Kimyrsa (oritavancin) for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.

Motif Bio plc announced today that the clinical-stage biopharmaceutical company received a complete response letter from the U.S. Food and Drug Administration regarding the new drug application for iclaprim for the treatment of acute bacterial skin and skin structure infections.

The U.S. FDA approved Paratek Pharmaceuticals Inc.’s Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.

Shares of Paratek Pharmaceuticals climbed in pre-market trading after the company announced a U.S. Food and Drug Administration advisory committee voted overwhelmingly in favor of intravenous and oral treatments for acute bacterial skin and skin structure infections (ABSSSI).

Motif Bio’s Phase III drug candidate iclaprim hit primary endpoints in treating patients with acute bacterial skin and skin structure infections (ABSSSI).

The U.S. Food and Drug Administration approved Medicines Co.’s antibacterial drug for patients with complicated urinary tract infections (cUTI).

Shares of Paratek rocketed upward after the antibiotics specialist posted a “for sale” sign on the doors.

The U.S. Food and Drug Administration approved a new treatment for patients with acute bacterial skin infections, made by privately held Melinta Therapeutics.

Cempra Inc. said its experimental oral drug to treat acute bacterial skin infections cleared a late-stage study.